Nicox announces third quarter 2014 financial update

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nicox announces third quarter 2014 financial update
  • Total revenues of €4.5 million in the 9 months to September 30 2014 (vs. €0.3 million in same period of 2013)
  • Completion of Aciex Therapeutics, Inc. acquisition significantly strengthens Nicox's therapeutic development pipeline
  • Positive phase 3 results for VESNEO (latanoprostene bunod) support strong commercial potential
  • Acquisition of Doliage in France strengthens established revenue streams and marketing infrastructure

SOPHIA ANTIPOLIS, France, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today provides an update on its revenues and cash position for the first nine months of 2014.

Michele Garufi, Chief Executive Officer of Nicox , commented: " In the third quarter of this year, we have achieved important progress in building our therapeutic ophthalmic pipeline, thanks to the positive pivotal phase 3 results for VESNEO and the recently completed acquisition of Aciex Therapeutics, Inc. Nicox now has two product candidates which have completed phase 3 trials and this increases our confidence in our future prospects as a competitive International Ophthalmic Group. "

Financial summary for the first nine months of 2014

Revenues

The company posted total revenues of €4.5 million for the first nine months of 2014, compared with €0.3 million for the same period in 2013.

The nine months sales revenues represent the first significant recurring revenues from Nicox's growing portfolio of ophthalmic products, currently in the launch phase, including: established sales from Nicox's Italian subsidiary; initial sales from AdenoPlus ® and the Xailin(TM) range in Europe and the rest of the world (ROW), outside North America; and initial sales of Sjö(TM) and RetnaGene(TM) in the United States (US). Nicox markets AdenoPlus ® , a diagnostic test that aids in the differential diagnosis of conjunctivitis, and Xailin(TM), a range of ocular lubricants for dry eye, directly in the 5 major European markets and in other ROW countries through distributors. In addition, the Group's US subsidiary Nicox Inc. launched the RetnaGene(TM) portfolio of tests for evaluation of the risk of advanced Age-related Macular Degeneration (AMD) at the end of June 2014 and continues to roll-out Sjö(TM), for the early detection of Sjögren's syndrome, throughout the US.

Other revenues include an upfront payment of €0.5 million linked to the exclusive distribution agreement granted to Nitto Medic in August 2014 for the commercialization of AdenoPlus ® in the Japanese market.

The table below shows the revenues for the first nine months of 2014 and 2013:

(in million euros) September 30, 2014 September 30, 2013
Sales US 0.8 0.2
Sales Europe / ROW 3.2 0.1
Total sales 4.0 0.3
Other revenues 0.5 -
TOTAL REVENUES 4.5 0.3

Cash, cash equivalents and current financial instruments

The Company's cash, cash equivalents and current financial instruments amounted to €32.9 million as of September 30, 2014. As of September 30, 2014, Nicox's bank indebtedness was limited to €0.3 million following the consolidation of new entities.

Third-quarter and post-third quarter operational summary

Acquisition of Aciex Therapeutics, Inc.

In July 2014, Nicox signed an agreement to acquire all of the outstanding equity of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company with a strong near-term pipeline of therapeutics addressing major segments of the ophthalmic market. The acquisition was completed on October 24, 2014 following the approval of Nicox's shareholders at an Extraordinary General Meeting held on October 22, 2014. Nicox exchanged 20,627,024 newly issued Nicox shares for 100% of Aciex's shares. The transaction also includes contingent value rights giving right to shares for a potential additional value of up to $55 million, based on the potential US FDA approval(s) of AC-170 and of two additional undisclosed products within a pre-determined period.

VESNEO: Positive top-line phase 3 results to support FDA filing

VESNEO ® (latanoprostene bunod) is a nitric oxide (NO)-donating prostaglandin F2-alpha analog currently in phase 3 clinical development with Bausch + Lomb, a division of Valeant Pharmaceuticals International, Inc., for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. Positive top-line results from the pivotal phase 3 studies APOLLO and LUNAR conducted with VESNEO were announced in September 2014. Both studies met their primary efficacy endpoint and showed positive results on a number of secondary endpoints. Bausch + Lomb expects to submit a New Drug Application (NDA) to the FDA for the approval of VESNEO in mid-2015, with a potential launch in the US in the first half of 2016, pending FDA approval.

Under the terms of the worldwide licensing agreement signed between Nicox and Bausch + Lomb in March 2010, Nicox stands to receive potential additional regulatory and sales milestones from Bausch + Lomb of up to $162.5 million, which would result in net milestones for Nicox of up to $132.5 million following payments due to Pfizer as part of 2009 agreement. Nicox would also receive potential net tiered royalties on sales, pending FDA approval, ranging from 6% to 11% following payments due to Pfizer. In addition, Nicox exercised its option to co-promote latanoprostene bunod in the US in August 2014.

A review article on the potential of NO in glaucoma, written by scientists from both Bausch + Lomb and Nicox, was published in August 2014 in Investigative Ophthalmology and Visual Science (IOVS). 1

Acquisition of French ophthalmic company Doliage

In September 2014, Nicox acquired 100% of the shares of Doliage, a privately-held French ophthalmic company, for €5 million in newly-issued Nicox shares. The acquisition provides Nicox with an established and profitable ophthalmic business in France, with Doliage's sales totaling €2.6 million in 2013.

Acquisition of Carragelose ® eye drop program

In September 2014, Nicox acquired the Carragelose ® anti-viral eye drop program from Marinomed Biotechnologie GmbH for a total of €2.65 million in newly issued Nicox shares and up to €2.65 million in potential additional cash payments. The acquisition provides Nicox with an innovative anti-viral ophthalmic product to be developed under the name 'Xailin Viral', which could be launched in Europe as a medical device within two years, pending CE marking.

Xailin Gel launch

In October 2014, Nicox launched Xailin Gel, an innovative multidose carbomer gel lubricant (medical device) that becomes preservative-free in the eye, in Europe. Once Xailin Gel is in contact with the eye surface, the substance released by the preservative is converted to water and oxygen by ocular enzymes, making Xailin Gel 'preservative-free in the eye'. Xailin Gel follows Xailin Night and Xailin Fresh as the third medical device to be introduced in the Xailin(TM) range of dry eye lubricants. Other ocular lubricants are planned to be launched as part of the Xailin range by the end of 2014.

Update on US operations

In July 2014, Nicox acquired the extension of the rights to market Sjö(TM), an advanced diagnostic panel for the early detection of Sjögren's syndrome, to all healthcare practitioners in North America. In July 2014, Nicox and Rapid Pathogen Screening (RPS ® ) agreed to restructure the terms of their partnership in North America. RPS ® has assumed responsibility for marketing AdenoPlus ® to eye care professionals in North America, as well as two other diagnostic products currently in development, and will pay Nicox royalties on sales. Nicox retains rights to commercialize AdenoPlus ® and the previously licensed development products in all markets outside North America.

Update on ROW distributions agreements

In August 2014, Nicox entered into an exclusive agreement with Nitto Medic, a leading Japanese ophthalmic company, for the distribution of AdenoPlus ® in Japan. In October 2014, Nicox entered into an exclusive agreement with OptiMed, a leading Australian company distributing ophthalmic diagnostic and therapeutic products, for the distribution of its product portfolio, including AdenoPlus ® and the Xailin(TM) range, in Australia and New Zealand.

Board of Directors

In August 2014, Nicox's Board agreed to co-opt Adrienne Graves, former CEO of Santen Inc., the US subsidiary of Santen, and Luzi von Bidder, former Chairman of Acino Holding AG and former Chairman and CEO of Novartis Ophthalmics AG, as members of the Board, to replace Vaughn Kailian and Vicente Anido. The co-options of Dr. Graves and of Mr von Bidder were approved by Nicox's shareholders at the General Meeting held on October 22, 2014. Shareholders also approved the appointment of Les Kaplan to the Company's Board of Directors. Mr. Kaplan is the former Executive Chairman of Aciex Therapeutics, Inc. and former Executive Vice President and President, Research and Development of Allergan, Inc.

Management team

In August 2014, Nicox appointed Michael Bergamini, Ph.D., as Chief Scientific Officer (CSO) and Executive Vice President. Dr. Bergamini brings over 30 years of experience in the eye care industry and has played key roles in the discovery, translation, development, registration, and US and international launch of a number of pharmaceuticals, as well as several medical device products.

Following a review of the needs of the business, Nicox and Evelyne Nguyen have jointly agreed to change her collaboration framework to part-time Corporate Finance Advisor to support the Group's Corporate Finance activities. She will continue to be a member of Nicox's Executive Committee.
...................................

References:

  1. Cavet ME, Vittitow JL, Impagnatiello F, Ongini E, Bastia E. Nitric Oxide (NO): An Emerging Target for the Treatment of Glaucoma. Invest Ophthalmol Vis Sci. 2014, 55(8): 5005-15

...................................

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is latanoprostene bunod, a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com .
..................................

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in: the 4 th chapter of the "Document de référence, rapport financier annuel et rapport de gestion 2013" filed with the French Autorité des Marchés Financiers (AMF) on April 2 nd , 2014; the "Rapport semestriel financier et d'activité au 30 juin 2014"; the 5 th chapter of the "Actualisation du Document de Référence 2013" filed with the AMF on September 30, 2014 (D. 14-0271-A01); and the section B of the 'Document E' registered with the AMF on September 30, 2014 (E.14-060). All these documents are available on Nicox's website ( www.nicox.com ).

...................................

Contacts  
Nicox Gavin Spencer  |   Executive Vice President Corporate Development
  +33 (0)4 97 24 53 00 | communications@nicox.com
   
Media Relations  
   
United Kingdom Jonathan Birt
  +44 7860 361 746 | jonathan.birt@ymail.com
   
France Caroline Courme | Communication Manager
  +33 (0)4 97 24 53 43 | courme@nicox.com

Press release http://hugin.info/143509/R/1866837/655824.pdf

HUG#1866837

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 225

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 71

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 114

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 71

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 88

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Tonum and Euvita Link Supplements to Personalized Care

Updated Category News Views 8

Muscle loss has become the awkward footnote in the GLP-1 weight-loss boom, and Tonum Health is trying to put that concern nearer the center of the care conversation. Its newly announced partnership with euvita health places Tonum's supplements and functional nutrition products inside a physician-led platform built around biomarker testing, hormone and peptide therapy,...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 83

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 70

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 296

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 20

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading

Top 5 Most Recently Viewed Articles

D.Law's New Office: A Major Step Forward in Growth

Updated Category News Views 158

D.Law Opens New Office in Glendale D.Law is excited to announce a significant milestone in its expansion with the launch of its new office at 450 N. Brand Blvd, Suite 840. This important development represents more than just a new location; it embodies the firm's dedication to growing its capabilities and providing better service to its clients. A New Beginning for D.Law...

Continue Reading
Innovative Hunting Shack Designed for Comfort and Covert Use

Updated Category News Views 155

Revolutionizing the Hunting Experience Hunting requires a blend of stealth, comfort, and practicality, all of which have inspired an exciting innovation: the specially designed hunting shack. An inventor focused on optimizing the hunting experience has created this remarkable mobile structure, ideal for outdoor enthusiasts seeking to enhance their hunting adventures. A...

Continue Reading
ALTA Honors Senate for Confirming Pulte as FHFA Director

Updated Category News Views 236

ALTA Celebrates Senate Confirmation of Bill Pulte The American Land Title Association (ALTA) has expressed its appreciation to the U.S. Senate following the confirmation of Bill Pulte as the new director of the Federal Housing Finance Agency (FHFA). This announcement marks a significant moment for both ALTA and the housing industry. Bill Pulte’s Role at FHFA Bill Pulte,...

Continue Reading
Celebrating Talar Guedikian's Achievement as Paralegal of the Year

Updated Category News Views 181

Talar Guedikian Named 2025 AAJ Paralegal of the Year The legal community is buzzing with excitement as Talar Guedikian, a dedicated Senior Litigation Paralegal, has been honored with the prestigious title of the 2025 AAJ Paralegal of the Year. This recognition, sponsored by Advocate Capital, showcases her exceptional capabilities and unwavering commitment to the legal...

Continue Reading
Bauer Hockey Welcomes Gillian Meek as New Executive Leader

Updated Category News Views 237

Bauer Hockey Appoints Gillian Meek as Executive Vice President Bauer Hockey, recognized globally as the leading manufacturer of hockey equipment and the premier brand within the sport, has made a significant executive change. The company has welcomed Gillian Meek as its new Executive Vice President and General Manager. This strategic move was announced recently, and it...

Continue Reading